{"filing":{"accession_number":"0001671927-26-000026","cik":"0001671927","ticker":"IMCR","company_name":"Immunocore Holdings plc","form":"8-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"imcr-20260914.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1671927/000167192726000026/imcr-20260914.htm"},"events":[{"id":33105,"run_id":30429,"accession_number":"0001671927-26-000026","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Immunocore announced achievement of target enrollment (540 patients) in the Phase 3 TEBE-AM registrational trial for tebentafusp in previously treated advanced melanoma, with topline overall survival data expected as early as end of 2026. This is a material clinical development milestone for a commercial-stage biotech company with an approved product (KIMMTRAK), as it represents progress toward potential label expansion and addresses a significant unmet medical need. The event is operational/strategic rather than financial, governance, legal, or existential in nature, and does not fit the specific categories of earnings release, M\u0026A, impairment, or other named types.","company_name":"Immunocore Holdings plc","ticker":"IMCR","filing_date":"2026-09-14","form":"8-K","submitted_at":null,"items":[{"id":36453,"accession_number":"0001671927-26-000026","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Immunocore announced achievement of target enrollment (540 patients) in the Phase 3 TEBE-AM registrational trial for tebentafusp in previously treated advanced melanoma, with topline overall survival data expected as early as end of 2026. This is a material clinical development milestone for a commercial-stage biotech company with an approved product (KIMMTRAK), as it represents progress toward potential label expansion and addresses a significant unmet medical need. The event is operational/strategic rather than financial, governance, legal, or existential in nature, and does not fit the specific categories of earnings release, M\u0026A, impairment, or other named types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T11:16:40.325911+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36453,"accession_number":"0001671927-26-000026","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Immunocore announced achievement of target enrollment (540 patients) in the Phase 3 TEBE-AM registrational trial for tebentafusp in previously treated advanced melanoma, with topline overall survival data expected as early as end of 2026. This is a material clinical development milestone for a commercial-stage biotech company with an approved product (KIMMTRAK), as it represents progress toward potential label expansion and addresses a significant unmet medical need. The event is operational/strategic rather than financial, governance, legal, or existential in nature, and does not fit the specific categories of earnings release, M\u0026A, impairment, or other named types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T11:16:40.325911+00:00","company_name":"Immunocore Holdings plc","ticker":"IMCR","filing_date":"2026-09-14"}]}